TLR7 and neoplasm: The rationale of the therapeutic combination was that radiotherapy would provide tumor antigens, while the TLR7/8 agonist would stimulate antigen-presenting cells to process and present these antigens in order to induce and augment an immune response to the tumor (Fig. 1).